← Leaderboards
Alfred I. Geller
Children'S Hospital Boston
$8,338,960
Attributed
$8,338,960
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $518.2K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,338,960 · 6
By mechanism
R01$8,338,960 · 6
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyNervous System DisorderRattusDopamineParkinson DiseaseSimplexvirusProteinsVectorNeuronsGenesGene TransferPhysiologyEnzymesTransfection /Expression VectorComplexLearningBrainGene ExpressionBinding (Molecular Function)Laboratory RatCellsAdeno-Associated Viral VectorNeurodegenerative DisordersCorpus Striatum Structure
Grant awards (33)
Targeted gene transfer across specific synapse types$319,375
R01 · FY2017 · NS · contact PI
Targeted gene transfer across specific synapse types$319,375
R01 · FY2016 · NS · contact PI
Targeted gene transfer across specific synapse types$324,020
R01 · FY2015 · NS · contact PI
Targeted gene transfer across specific synapse types$45,230
R01 · FY2015 · NS · contact PI
Targeted gene transfer across specific synapse types$369,250
R01 · FY2014 · NS · contact PI
Promoters for Long-term Expression from HSV-1 Vectors$248,311
R01 · FY2011 · NS · contact PI
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors$248,311
R01 · FY2011 · NS · contact PI
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors$250,844
R01 · FY2010 · NS · contact PI
Promoters for Long-term Expression from HSV-1 Vectors$250,844
R01 · FY2010 · NS · contact PI
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors$253,378
R01 · FY2009 · NS · contact PI
Promoters for Long-term Expression from HSV-1 Vectors$253,378
R01 · FY2009 · NS · contact PI
Promoters for Long-term Expression from HSV-1 Vectors$11,470
R01 · FY2009 · NS · contact PI
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors$253,378
R01 · FY2008 · NS · contact PI
Promoters for Long-term Expression from HSV-1 Vectors$253,378
R01 · FY2008 · NS · contact PI
Targeted Gene Transfer, to Specific Types of Neurons, with HSV-1 Vectors$253,378
R01 · FY2007 · NS · contact PI
High-titer helper virus-free HSV-1 vectors$244,630
R01 · FY2007 · AG · contact PI
High-titer helper virus-free HSV-1 vectors$251,937
R01 · FY2006 · AG · contact PI
Long-Term expression from HSV-1 vectors$239,340
R01 · FY2006 · NS · contact PI
High-titer helper virus-free HSV-1 vectors$258,000
R01 · FY2005 · AG
Long-Term expression from HSV-1 vectors$245,100
R01 · FY2005 · NS
GENE THERAPY FOR AGING DISORDERS$274,409
R01 · FY2004 · AG
Enhanced HSV-1 Vector Particles for Neural Gene Therapy$265,000
R01 · FY2004 · NS
High-titer helper virus-free HSV-1 vectors$258,000
R01 · FY2004 · AG
Long-Term expression from HSV-1 vectors$245,100
R01 · FY2004 · NS
GENE THERAPY FOR AGING DISORDERS$266,422
R01 · FY2003 · AG
Enhanced HSV-1 Vector Particles for Neural Gene Therapy$265,000
R01 · FY2003 · NS
High-titer helper virus-free HSV-1 vectors$258,000
R01 · FY2003 · AG
Long-Term expression from HSV-1 vectors$245,100
R01 · FY2003 · NS
Enhanced HSV-1 Vector Particles for Neural Gene Therapy$265,000
R01 · FY2002 · NS
GENE THERAPY FOR AGING DISORDERS$258,660
R01 · FY2002 · AG
GENE THERAPY FOR AGING DISORDERS$294,460
R01 · FY2001 · AG
Enhanced HSV-1 Vector Particles for Neural Gene Therapy$265,000
R01 · FY2001 · NS
GENE THERAPY FOR AGING DISORDERS$285,882
R01 · FY2000 · AG